Fresenius Medical Care reported strong operational and financial progress in the second quarter of 2025, with organic revenue growth of 7% and double-digit operating income growth. Operating income, excluding special items, increased by 13% at constant currency to EUR 476 million, resulting in a margin of 9.9%.
The company confirmed its full-year 2025 outlook for positive to low-single digit percentage revenue growth and high-teens to high-twenties percentage operating income growth, excluding special items. The FME25+ transformation program continued its momentum, delivering EUR 58 million in additional sustainable savings during the quarter, contributing to the total target of EUR 1,050 million by year-end 2027.
Fresenius Medical Care announced its intention to initiate the first tranche of its previously announced EUR 1 billion share buyback program in August, reflecting confidence in its strong cash generation and commitment to shareholder returns. The net leverage ratio further improved to 2.7x in Q2 2025, down from 2.8x in Q1 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.